JPH024576B2 - - Google Patents

Info

Publication number
JPH024576B2
JPH024576B2 JP54132510A JP13251079A JPH024576B2 JP H024576 B2 JPH024576 B2 JP H024576B2 JP 54132510 A JP54132510 A JP 54132510A JP 13251079 A JP13251079 A JP 13251079A JP H024576 B2 JPH024576 B2 JP H024576B2
Authority
JP
Japan
Prior art keywords
microparticles
drug
cervix
progesterone
uterus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP54132510A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5555114A (en
Inventor
Aaru Betsuku Rii
Efu Furawaazu Chaaruzu
Aaru Kauzaa Donarudo
Shii Tankarii Arubaato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stolle Research and Development Corp
Original Assignee
Stolle Research and Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Research and Development Corp filed Critical Stolle Research and Development Corp
Publication of JPS5555114A publication Critical patent/JPS5555114A/ja
Publication of JPH024576B2 publication Critical patent/JPH024576B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP13251079A 1978-10-17 1979-10-16 Fine drug Granted JPS5555114A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95210978A 1978-10-17 1978-10-17

Publications (2)

Publication Number Publication Date
JPS5555114A JPS5555114A (en) 1980-04-22
JPH024576B2 true JPH024576B2 (enExample) 1990-01-29

Family

ID=25492596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13251079A Granted JPS5555114A (en) 1978-10-17 1979-10-16 Fine drug

Country Status (3)

Country Link
JP (1) JPS5555114A (enExample)
BE (1) BE879442A (enExample)
ZA (1) ZA795549B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2664906B2 (ja) * 1987-08-13 1997-10-22 ストール・リサーチ・アンド・デイベロップメント・コーポレーション 改良された哺乳類の免疫法
FR2619503A1 (fr) * 1987-08-20 1989-02-24 Hutchinson Application de microcapsules a la fabrication d'un dispositif prophylactique en materiau elastomere, comme un preservatif ou analogue, et son procede de fabrication
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration

Also Published As

Publication number Publication date
BE879442A (fr) 1980-04-16
JPS5555114A (en) 1980-04-22
ZA795549B (en) 1980-11-26

Similar Documents

Publication Publication Date Title
US4756907A (en) Active/passive immunization of the internal female reproductive organs
US4585651A (en) Active/passive immunization of the internal female reproductive organs
US4732763A (en) Active/passive immunization of the internal female reproductive organs
Brannon-Peppas Novel vaginal drug release applications
EP0799025B1 (en) Intravaginal drug delivery devices for the administration of 17beta-oestradiol precursors
Benagiano et al. Contraception today
CA1143289A (en) Microparticle drug delivery system
ES2337129T3 (es) Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
Johansson et al. New delivery systems in contraception: vaginal rings
JPH09131404A (ja) 腟内薬剤放出器具
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
CN1154067A (zh) 含有竞争性黄体酮拮抗和孕激素的复合物用于制备治疗子宫内膜异位或子宫平滑肌瘤的药物
US20190201418A1 (en) Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
Lee et al. Drug delivery: Vaginal route
Beck et al. Long-acting injectable microsphere formulation for the parenteral administration of levonorgestrel
JPH024576B2 (enExample)
BR112020021995A2 (pt) administração direcionada de progestinas e estrogênios através de dispositivos de anel vaginal para controle de fertilidade e produtos trh
CA2517778A1 (en) Extended transdermal contraceptive regimens
WO2012121778A1 (en) Treatment of endometriosis by intravaginal administration of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
Lipp Novel drug delivery systems for steroidal hormones
JP2009539759A (ja) 経口１相性低用量避妊薬に対する新しい投与計画
US20200179274A1 (en) Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof
JP2001505589A (ja) 雄の避妊薬としてのアンドロゲン及び非避妊アンドロゲン補充体
Ye et al. Research progress of progesterone preparations: a mini review
US20230404911A1 (en) Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof